In a move set to reshape the Canadian pharmaceutical landscape, Knight Therapeutics Inc. has agreed to acquire Paladin Pharma from Endo Inc. for up to $99 million. The transaction, announced Tuesday, underscores Knight’s aggressive expansion strategy, further cementing its dominance in Canada and Latin America.

The deal, which includes an upfront cash payment of $84 million, also features an additional $15 million in milestone-based payments, dependent on performance metrics, according to Knight’s official statement.

A Strategic Divestiture for Endo

For Endo Inc., the sale represents a pivotal shift in its corporate strategy. The company, known for developing life-enhancing therapies, is streamlining its focus on core growth assets, with Paladin’s divestiture serving as a key milestone in that transformation.

"This divestiture is an important step forward in our strategic transformation," said Scott Hirsch, interim CEO of Endo. "We are confident that Paladin is positioned for continued success in the Canadian market, and Knight is the ideal partner to drive its next phase of growth."

Endo’s decision to offload Paladin is part of a broader restructuring initiative, aligning its portfolio with high-value, high-growth therapeutic areas.

A Homecoming for Paladin

For Knight Therapeutics, this acquisition is more than just a business deal—it’s a reunion. Paladin Pharma was originally co-founded by Knight’s Executive Chairman, Jonathan Ross Goodman, making this acquisition deeply personal and strategic.

"The reunion of Paladin and Knight is both financially attractive and personally gratifying," said Goodman.

Knight, a specialty pharmaceutical powerhouse, focuses on acquiring, licensing, and commercializing innovative prescription drugs across Canada and Latin America. The integration of Paladin into Knight’s operations is expected to deliver immediate financial synergies and boost its cash flow generation.

"This transaction significantly increases the scale of our Canadian business," said Samira Sakhia, President and CEO of Knight Therapeutics. "It adds a stable portfolio of revenue-generating pharmaceuticals, fueling our expansion in both Canada and Latin America."

Deal Timeline and Regulatory Approvals

The acquisition is set to close by mid-2025, pending the fulfillment of customary closing conditions. While legal counsel details for Knight’s advisors at Davies Ward Phillips & Vineberg LLP were not fully disclosed, Endo Inc. was represented by Davis Polk & Wardwell LLP and Torys LLP.

As the pharmaceutical industry consolidates, Knight’s latest move marks a bold step forward, positioning the company as a dominant force in the North American market.